Home / Business and Economy / J&J Stock Soars: Mega-Cap Health Giant Beats Market
J&J Stock Soars: Mega-Cap Health Giant Beats Market
30 Aug
Summary
- Johnson & Johnson's market cap exceeds $640 billion, classifying it as a mega-cap stock.
- The stock has surged 52.8% over the past year, significantly outperforming its sector ETF.
- Q2 2026 earnings exceeded expectations, with sales up 6.6% year-over-year to $25.31 billion.
New Brunswick, New Jersey-based Johnson & Johnson, a diversified global healthcare giant, holds a substantial market capitalization of $640.5 billion, firmly placing it in the mega-cap stock category. Operating through its Innovative Medicine and MedTech segments, the company has demonstrated impressive recent performance.
As of August 30, 2026, J&J's stock is trading near its 52-week high, having rallied 52.8% over the past 52 weeks and 29.5% in 2026. This upward trend significantly outpaces the State Street Consumer Staples Select Sector SPDR Fund. Trading above key moving averages indicates sustained positive momentum.
The company's Q2 2026 earnings, released on July 15, showed a 6.6% year-over-year sales increase to $25.31 billion, with adjusted EPS of $2.90, exceeding forecasts. Consequently, J&J raised its full-year 2026 outlook, projecting sales of $101.1 billion and adjusted EPS of $11.58.
Despite its strong performance, J&J has underperformed competitor Eli Lilly and Company over the past year, which saw a 60.5% surge. Nonetheless, J&J's consistent pharmaceutical growth, resilient MedTech business, and improved earnings outlook have bolstered investor confidence.
